European Journal of Cancer and Clinical Oncology
Volume 26, Issue 1, January 1990, Pages 1-3
CommentaryResistance to cisplatin: How to deal with the problem?
References (16)
- et al.
Mechanisms of resistance to cis-diamminedichloroplatinum(II) in a rat ovarian carcinoma cell line
Eur J Cancer Clin Oncol
(1989) - et al.
Augmentation of Adriamycin®, melphalan and cisplatin cytotoxicity in drug-resistant and sensitive human ovarian carcinoma cell lines by buthionine sulfoximine mediated glutathione depletion
Biochem Pharmacol
(1985) - et al.
High dose carboplatin in the treatment of lung cancer and mesothelioma: a phase I dose escalation study
Eur J Cancer Clin Oncol
(1987) - et al.
Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II)
Cancer Res
(1987) - et al.
Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues
Cancer Res
(1987) - et al.
Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells
Cancer Res
(1987) - et al.
Cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells
Cancer Res
(1988) - et al.
Increased cytotoxicity and reversal of resistance to cis-diamminedichloroplatinum(II) with entrapment of cis-bis-neodecanoato-trans-BR-1,2-diaminocyclohexaneplatinum(II) in multilamellar lipid vesicles
Cancer Res
(1988)
There are more references available in the full text version of this article.
Cited by (31)
Novel bile acid derivatives (BANBs) with cytostatic activity obtained by conjugation of their side chain with nitrogenated bases
2007, Biochemical PharmacologyCitation Excerpt :More recently, their beneficial cytostatic properties against intestinal tumors have been also proposed [6,7]. One of the factors that often reduce the clinical usefulness of cisplatin-related cytostatic drugs is the development of resistance to them [8], which can be due in part to an up-regulation of export pumps. Although several agents able to block the efflux of cytostatic drugs through these transporters have been developed, the pharmacologically efficient doses of currently available chemosensitizing agents are so high that they cannot be used in clinical practice owing to their noxious side effects [9].
Cisplatin and low dose rate irradiation in cisplatin resistant and sensitive human glioma cells
1996, International Journal of Radiation Oncology Biology PhysicsOvarian cancer, Part I: Biology
1992, Current Problems in CancerWhat's New in Cytostatic Drug Resistance and Pathology
1991, Pathology Research and Practice
- ∗
Jean-Luc Canon is Research Assistant of the National Fund for Scientific Research (Belgium).
Copyright © 1990 Published by Elsevier Ltd.